Walgreens has launched a next-day prescription-delivery service. The pharmacy partnered with FedEx on the nationwide service meant to compete with Amazon after the Seattle-based company’s acquisition of PillPack this year. (MM&M) The Amazon-PillPack deal hasn’t closed, but pharmacies such as Walgreens and CVS are beefing up services to compete. (CNBC)

AbbVie halted a cancer drug trial after patients taking its treatment showed shorter survival times. The trial was testing the drug Rova-T in advanced small-cell lung cancer. There are separate trials for other forms of lung cancer and neuroendocrine tumors. The pharma company bought the drug two years ago in an estimated $10.2 billion deal. (Business Insider)

A Senate bill has been introduced that would penalize pharma companies for gaming the Medicaid system. The bill would introduce a financial penalty for drugmakers that knowingly misclassified a drug with Medicaid. The bill is thought to be a response to Mylan categorizing its EpiPen as a generic to avoid paying higher rebates to Medicaid. (BioPharma Dive)

Supernus Pharmaceuticals’ ADHD treatment met its goal in two late-stage studies. The drug is being tested on children six to 11 years old. Supernus is planning to submit its application to the FDA in 2019 and bring the drug to market in 2020. (Reuters)

Open Health and Peloton Advantage are merging to create a trans-Atlantic healthcare communications firm. The new entity will be led by Open Health chief executive David Rowley. The firms said that together, they will work with 90% of the world’s top 40 pharmaceutical companies. (MM&M)